Even though olaparib as a single agent has little effect on tumors without BRCA mutations, the capacity of PARP inhibitors for tumor radiosensitization has been confirmed in a number of in vitro and in vivo models 24, 33. This evidence concerns the gene PARP1 and neoplasm.